Author

M Baker

Observed institutions: University of Toronto, Columbia University

OpenAlex ID: A5111375868

A Phase I Study of Swainsonine in Patients With Advanced Malignancies

1993 · P E Goss, J Baptiste, et al. · Journal of Immunotherapy · 46

Deoxycytidine preferentially protects normal versus leukemic myeloid progenitor cells from cytosine arabinoside-mediated cytotoxicity

1987 · K Bhalla, W MacLaughlin, et al. · Blood · 33

A phase II controlled study of a combination of the immune modulator, lentinan, with didanosine (ddI) in HIV patients with CD4 cells of 200-500/mm3.

1995 · M Gordon, M Guralnik, et al. · PubMed · 28

Measuring swainsonine in serum of cancer patients: phase I clinical trial

1994 · J A Baptista, P Goss, et al. · Clinical Chemistry · 20

Deoxycytidine stimulates the in vitro growth of normal CFU-GM and reverses the negative regulatory effects of acidic isoferritin and prostaglandin E1

1986 · K Bhalla, J Cole, et al. · Blood · 12

Phase I clinical and pharmacologic study of deoxycytidine.

1988 · K Bhalla, M Birkhofer, et al. · PubMed · 6

Effect of deoxycytidine on the metabolism and cytotoxicity of 5-aza-2'-deoxycytidine and arabinosyl 5-azacytosine in normal and leukemic human myeloid progenitor cells.

1987 · K Bhalla, J Cole, et al. · PubMed · 6

Differential effect of deoxycytidine on pyrimidine antagonist mediated growth suppression in normal versus leukemic human myeloid progenitor cells

1985 · Kapil N. Bhalla, M Baker, et al.

Works count: 8

Citation count: 151

H-index: 6

I10-index: 5